Latest Conference Articles

New ERS findings show patients hospitalized for COVID-19 bettered from timelier, personalized rehabilitation plans.

A $25 genetic test could inform physicians on optimal controller therapy for children and adolescents with asthma.

In a new study presented at ERS 2020, Dr. Mark Levy discusses how a digital inhaler reduces the amount of people who use their inhaler incorrectly.

The risk of cardiovascular hospitalizations was associated with increasing PM10 at lag 0.

Manan Pareek, MD, PhD gives an overview about what is currently known about COVID-19 and cardiovascular risk.

In a poster presented at ERS, researchers find the complement and coagulation cascades pathway was up-regulated in response to airway presence of Moraxella genera that might suggest an activation of systemic innate immunity in response to Moraxella.

Three patients with unclassified interstitial lung disease had a change in diagnosis during the study’s follow-up period.

Of the 2199 patients who received a renal transplant, only 8 were treated for active tuberculosis.

In a poster presented at the ERS Virtual Conference, investigators identify the relative rate of severe asthma exacerbations using LAMA monotherapy.

These guidelines set by ESC and EAS 2019 established treatment goals for LDL-C, non-HDL-C, and Apo-B in patients at high risk for cardiovascular disease.

The new equation model has shown to be more accurate than the Framingham Lifetime Risk equation and Pooled Cohort Equation.

Post hoc analysis of REAL-CAD shows the cholesterol metric does not serve to inform statin treatment control of coronary artery disease.

The congress president shares her favorite sessions, and ideas to integrate virtual setting successes into next year's meeting.

New data shows that high BMI individuals who were in the lowest polygenic score quintile had a 5-fold greater risk of diabetes than those with low BMI and a high polygenic score.

According to late breaking data, younger women exhibit a decreased risk for heart attack mortality due to estrogen’s protective effect

What ESC has learned about the benefits and difficulties of online-only forums.

Evolocumab and alirocumab produced LDL-C reduction in patients regardless of underlying mutations, investigators reported.

This underscores a need to reinvent cities and address environmental risk factors that are associated with increased risk for cardiovascular diseases.

Myocardial infarction patients were provided ECG readings as reliable as those provided by standard devices.

Studies have shown that heat-related cardiovascular events have increased over recent years.

New cohort data shows that at least 40% of COVID-19 positive patients had CV risk factors, such as diabetes and hypertension.

Dapagliflozin and empagliflozin are shown to minimize CV events in patients with heart failure and a reduced ejection fraction.

A look at how a major international cardiovascular meeting changed its structure in 4 months.

A look at how different organisms are influenced differently by harmful foods or common therapies linked to cardiovascular risks.

Investigators did note that belief in statin use was weaker in patients with confirmed statin associated muscle symptoms when compared with non-SAMS patients.

New findings suggest the "obesity paradox" may be explained by rates of exercise among women.

Accurately assessing lifetime risk in patients with developing atherosclerosis may help reduce CV disease risk earlier in life.

The CLEAR Harmony open-label extension study reports on the long-term effects of BA treatment for hypercholesterolemia.